The Role of Neutrophils and Trail in BCG Immunotherapy for Bladder Cancer

$0.00

Mark P. Simons, Kevin G. Leidal , Sally J. McCormick, Thomas S. Griffith and William M. Nauseef (Editors)
University of Iowa, Iowa City, IA, USA, and others

Series: Cell Biology Research Progress, Cancer Etiology, Diagnosis and Treatments
BISAC: MED062000

Most bladder tumors are non-muscle invasive at diagnosis and have a high rate of local recurrence and progression even after local surgical therapy. Thus, many patients require lifelong follow-up examinations that include additional prophylactic treatments in the event of recurrence. Despite over 30 years of clinical use, the anticancer mechanism of BCG in the treatment of bladder cancer has not been clearly defined.

Proteins located in the three distinct granule populations of mature PMN are compartmentalized concomitant with their synthesis during cell maturation, rather than being differentially segregated by localizing markers that target a specific protein to a particular granule. This new book presents research including the understanding PMN production, localization, and release of TRAIL which is important in the design of future BCG-based bladder tumor immunotherapy protocols. (Imprint: Nova Biomedical)

Clear

Details

Table of Contents

ABSTRACT

INTRODUCTION

MYELOPOIESIS

PMN PHAGOCYTOSIS AND KILLING MECHANISMS

TRAIL AND APOPTOSIS

PMN, URINARY TRACT INFECTIONS, AND BCG THERAPY

LIMITED TRANSCRIPTIONAL CONTROL OF PMN RESPONSES

IFN AUGMENTS THE TOTAL AMOUNT OF TRAIL STORED IN PMN

ANALYSIS OF TRAIL BIOSYNTHESIS IN IFN-TREATED PMN

SUBCELLULAR LOCALIZATION AND SECRETION OF DE NOVO TRAIL FROM IFN-PRIMED PMN

KINETICS OF TRAIL RELEASE FROM IFN-TREATED PMN

SUMMARY

ACKNOWLEDGEMENTS

REFERENCES

INDEX

Additional information

Binding